Medicare is Covering GLP-1 Starting July 2026: What to Know

In a landmark policy shift, Medicare will begin covering GLP-1 receptor agonist medications for weight loss starting July 2026. This change, made possible through provisions in the Treat and Reduce Obesity Act, will extend access to medications like Wegovy and Zepbound to millions of Medicare beneficiaries who previously had to pay entirely out of pocket. Here is everything you need to know about this historic coverage expansion.

What Changed and Why

Historically, Medicare Part D explicitly excluded coverage of medications prescribed solely for weight loss or cosmetic purposes. This exclusion was written into the original Medicare Modernization Act of 2003 and remained in place for over two decades, even as the medical understanding of obesity evolved dramatically.

The legislative change recognizes obesity as a chronic disease rather than a lifestyle choice. With over 40% of Americans over 65 classified as obese and GLP-1 medications showing benefits beyond weight loss, including cardiovascular risk reduction, the case for coverage became difficult to ignore. The SELECT trial demonstrating a 20% reduction in major cardiovascular events for semaglutide users was particularly influential in the policy debate.

Who Is Eligible

Not every Medicare beneficiary will automatically qualify for GLP-1 coverage. Based on the current implementation framework, eligibility criteria include:

• BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity
• Documented prior attempts at weight management through diet and exercise
• Prescription from a qualified provider who documents medical necessity
• Enrollment in Medicare Part D or a Medicare Advantage plan with Part D coverage

Medicare Advantage plans may implement their own formulary decisions regarding which specific GLP-1 medications they cover, so coverage details will vary by plan. Traditional Medicare Part D plans will follow CMS guidance on covered medications.

Which Medications Will Be Covered

The coverage applies to FDA-approved anti-obesity medications, which includes:

• Wegovy (semaglutide 2.4mg) - Novo Nordisk
• Zepbound (tirzepatide) - Eli Lilly
• Saxenda (liraglutide 3.0mg) - Novo Nordisk

Notably, Ozempic and Mounjaro are currently approved only for type 2 diabetes, not weight loss. Medicare already covers these for diabetes patients. The new coverage specifically addresses the gap for patients who need GLP-1 medications purely for weight management without a diabetes diagnosis.

What Will Medicare Beneficiaries Pay

Even with Medicare coverage, beneficiaries will have out-of-pocket costs. The exact amount depends on your specific Part D plan, but here is a general framework:

• Deductible phase: You pay the full negotiated price until meeting your Part D deductible (up to $590 in 2026)
• Initial coverage phase: You pay a copay or coinsurance (typically 25% of the drug cost)
• Coverage gap (donut hole): With the Inflation Reduction Act changes, out-of-pocket costs are now capped at $2,000 annually for Part D beneficiaries

The $2,000 annual out-of-pocket cap means that even at the highest medication prices, Medicare beneficiaries will not face unlimited costs. For a medication that costs $1,000 per month at list price, beneficiaries might pay the full negotiated rate for the first month or two, then copays, and hit the cap well before year-end.

How to Prepare Before July 2026

If you are a Medicare beneficiary interested in GLP-1 coverage, take these steps now:

1. Schedule a visit with your doctor to discuss weight management goals and establish documented medical necessity. Having prior records of weight-related health issues strengthens your case.
2. Review your Part D plan to understand your specific formulary and cost-sharing structure. Consider switching plans during the next open enrollment period if your current plan does not include favorable GLP-1 coverage.
3. Gather documentation of previous weight loss attempts, including diet programs, exercise regimens, or previous medications you have tried. This documentation may be required for prior authorization.
4. Ask about prior authorization requirements since most Medicare plans will require pre-approval before covering GLP-1 medications.

Impact on Medicare Advantage Plans

Medicare Advantage (MA) plans are required to cover the same benefits as traditional Medicare, but they have flexibility in how they implement coverage. Some MA plans may prefer one GLP-1 medication over another based on their negotiated pricing, require step therapy (trying a less expensive option first), or impose quantity limits. Review your plan's formulary carefully once the July 2026 coverage begins.

Concerns About Cost and Sustainability

The Congressional Budget Office has estimated that Medicare GLP-1 coverage could cost $35-50 billion over the first decade. This has raised concerns about premium increases for all Part D beneficiaries. Supporters argue that the cardiovascular and metabolic benefits of GLP-1 medications will reduce overall healthcare costs by preventing expensive conditions like heart attacks, strokes, and diabetes complications.

CMS is implementing utilization management strategies to control costs, including prior authorization requirements, preferred drug lists, and periodic re-evaluation of medical necessity. These measures are designed to ensure the medications reach patients who will benefit most while managing the fiscal impact.

What About Medicaid and Other Government Plans

While the Medicare change is the most significant development, several states have also expanded Medicaid coverage for GLP-1 weight loss medications. Tricare (military insurance) and VA healthcare have similarly updated their formularies. Check with your specific plan for current coverage details.

The Bottom Line

Medicare coverage of GLP-1 medications for weight loss represents a massive shift in how the US healthcare system treats obesity. For the millions of Medicare beneficiaries who could benefit from these medications, July 2026 marks the beginning of a new era of accessible treatment. Start preparing now by establishing your medical records and understanding your plan options.

Whether you are on Medicare or private insurance, finding the right GLP-1 provider matters. Take time to research and compare providers before committing, regardless of your insurance situation.